Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC) Meeting Abstract
| Authors: | DiNardo, C. D.; Dohner, H.; Zeidan, A. M.; Schuh, A. C.; Vyas, P.; Stein, E. M.; Wei, A. H.; de Botton, S.; Chen, C.; Lord-Bessen, J.; Martin-Regueira, P.; Lersch, F.; Gong, J.; Guo, S.; Shi, L.; Montesinos, P. |
| Abstract Title: | Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC) |
| Meeting Title: | 63nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398804268 |
| DOI: | 10.1182/blood-2021-147601 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1244 -- Hybrid meeting, also took place online -- Source: Wos |
